Ménégoz F, Martin E, Danzon A, Mathieu-Daudé H, Guizard A-V, Macé-Lesec'h J, Raverdy N, Pasquier B
Registres de l'Isère, FRANCIM.
Rev Epidemiol Sante Publique. 2006 Oct;54(5):399-406. doi: 10.1016/s0398-7620(06)76738-4.
In France, cancer incidence figures are produced by cancer registries covering only 13.5% to 16% of the whole population of the country. Thus, to produce national figures, estimates have to be computed. Registration disparities between registries concerning tumors of the Central Nervous System (CNS) could have biased these estimates.
National estimates are based on modelling of the incidence/mortality ratio. The most recent estimations for year 2000 were calculated by the French Cancer Registry Network (FRANCIM) and the department of biostatistics of Lyon University Hospital. Since benign tumors are not recorded in some cancer registries, a new estimate of the incidence of CNS tumors was produced by estimating the number of benign tumors in these registries.
In 2000 in France, the number of estimated cases of CNS tumors was 2697 in men and 2602 in women, with incidence rates (World standard) of 7.4 and 6.4 per 100,000 respectively. The incidence increased between 1978 and 2000, on an average by 2.25% per year in men and 3.01% per year in women. However, these estimates do not provide a correct picture of CNS incidence. First of all, pathological diagnoses are not performed in 3.5%-27.5% of the patients with CNS tumors registered in French registries. Second, figures for benign tumors (mainly meningiomas) were provided by only two of nine cancer registries. If benign tumors had been registered by all cancer registries, computed incidence would have increased by 12% for men and 26% for women.
Incidence of CNS tumors is increasing in France, as in many other countries. To improve comparability with other countries, French cancer registries should also collect data on benign tumors. The discrepancies observed between registries in the proportion of patients without information on histology show differences in diagnostic practices and should be the starting point for a survey on this topic.
在法国，癌症发病率数据由癌症登记处提供，而这些登记处仅覆盖该国总人口的13.5%至16%。因此，为了得出全国数据，必须进行估算。各登记处之间关于中枢神经系统（CNS）肿瘤的登记差异可能使这些估算产生偏差。
全国估算是基于发病率/死亡率比的模型。2000年的最新估算由法国癌症登记网络（FRANCIM）和里昂大学医院生物统计学系计算得出。由于一些癌症登记处未记录良性肿瘤，通过估算这些登记处中良性肿瘤的数量得出了中枢神经系统肿瘤发病率的新估算值。
2000年在法国，估计的中枢神经系统肿瘤病例数男性为2697例，女性为2602例，发病率（世界标准）分别为每10万人7.4例和6.4例。1978年至2000年间发病率有所上升，男性平均每年上升2.25%，女性平均每年上升3.01%。然而，这些估算并未准确反映中枢神经系统肿瘤的发病率情况。首先，在法国登记处登记的中枢神经系统肿瘤患者中，有3.5% - 27.5%的患者未进行病理诊断。其次，九个癌症登记处中只有两个提供了良性肿瘤（主要是脑膜瘤）的数据。如果所有癌症登记处都登记良性肿瘤，计算得出的发病率男性将增加12%，女性将增加26%。
与许多其他国家一样，法国中枢神经系统肿瘤的发病率正在上升。为了提高与其他国家的可比性，法国癌症登记处也应收集良性肿瘤的数据。各登记处在无组织学信息患者比例上的差异表明诊断实践存在不同，这应成为就此主题进行调查的起点。
